Every Form 4 that Neumora Therapeutics, Inc. (NMRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMRA filings page.
For Neumora Therapeutics, Inc. (NMRA), Chief Operating and Development Officer Aurora Daljit Singh reported multiple option exercises, share sales, and a new option grant. On August 20–21, 2026, Singh (and an affiliated family trust) exercised options to acquire a total of 176,060 shares of common stock at an exercise price of $0.72 per share and sold 176,060 shares in open-market transactions at weighted average prices around $1.51–$1.64 per share, including sales by the Aurora Family Trust, whose beneficiaries are immediate family members.
Separately, on August 20, 2026, Singh received a grant of 200,000 stock options with an exercise price of $1.52 per share, expiring on August 20, 2036. According to the vesting terms, 25% of these options vest on the first anniversary of August 20, 2026, and the remainder vest in equal monthly installments over the following three years.
Neumora Therapeutics, Inc. (NMRA) reported that Executive Chair of the Board Paul L. Berns received a stock option grant covering 500,000 shares of common stock at an exercise price of $1.52 per share. The option expires on August 20, 2036 and is held as a direct derivative position.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of August 20, 2026, and 1/48 of the total shares vest monthly thereafter so that the option becomes fully vested on the fourth anniversary of the Vesting Commencement Date.
Neumora Therapeutics, Inc. (NMRA) reported that officer Jason Duncan received a grant of stock options for 375,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036, with all options held as direct ownership.
According to the vesting terms, 25% of the option shares vest on August 20, 2027, the first anniversary of the Vesting Commencement Date, and the remaining shares vest in equal monthly installments over the following three years so that the grant is fully vested on the fourth anniversary.
Neumora Therapeutics, Inc. (NMRA) reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of stock options for 175,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036.
According to the vesting terms, 25% of the shares vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years, so that 100% of the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. (NMRA) reported that its President & CEO, Joshua Pinto, received a grant of stock options for 500,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years.
Neumora Therapeutics, Inc. (NMRA) reported insider transactions by Chief Operating and Development Officer Aurora Daljit Singh over August 17–19, 2026. Singh exercised stock options at an exercise price of $0.72 per share for a total of 243,753 shares of common stock and reported 277,773 shares sold in open-market transactions at weighted average prices within ranges running from about $1.46 to $1.70 per share. Some transactions involved shares held indirectly through the Aurora Family Trust, whose beneficiaries are members of Singh’s immediate family.
Neumora Therapeutics, Inc. director and 10% owner Kristina Burow received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036.
According to the grant terms, 100% of the shares subject to the option vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date. After this grant, the filing shows 80,000 derivative securities held directly.
Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Following this compensation award, Fust holds 80,000 derivative securities directly.
Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date, and expire on May 26, 2036.
Neumora Therapeutics, Inc. director Alaa Halawa received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 option shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date.
Neumora Therapeutics director Ho Maykin received a grant of stock options for 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date.
Neumora Therapeutics, Inc. officer Aurora Daljit Singh reported an open-market sale of 6,165 shares of common stock on February 17, 2026 at an average price of $3.555 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to vesting restricted stock units. After this transaction, Singh directly owned 82,770 common shares.
Neumora Therapeutics President Joshua Pinto reported a Form 4 showing the sale of 5,967 shares of common stock at $3.535 per share on February 17, 2026. According to the footnote, the shares were sold solely to satisfy tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, Pinto directly holds 57,783 shares, and an additional 152,167 shares are held indirectly by Maple DE Holdings LLC.
Neumora Therapeutics, Inc. director and officer Paul L. Berns reported an open-market sale of 9,819 shares of common stock on February 17, 2026. The shares were sold at a weighted average price of $3.5094 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
After the sale, Berns directly owned 7,395,185 shares of common stock. He also had indirect ownership of 133,097 shares held by LULU TRUST OF 2024 for specified beneficiaries, as noted in the footnotes.
Neumora Therapeutics officer Michael Lee Milligan reported an open-market sale of 1,436 shares of common stock at $3.565 per share. The February 17 transaction was executed under a pre-established Rule 10b5-1 trading plan that automatically sells shares on each covered restricted stock unit vesting date to satisfy withholding obligations.
After this sale, Milligan directly held 21,034 Neumora common shares. The filing describes an automated, plan-driven disposition rather than a discretionary trade decision.
Neumora Therapeutics, Inc. reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option covering 350,000 shares of common stock on January 8, 2026. The option has an exercise price of $2.33 per share and is held directly. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported a Form 4 transaction for officer Daljit Singh Aurora, its Chief Operating and Development Officer. On January 8, 2026, Aurora received a stock option to buy 750,000 shares of common stock at an exercise price of $2.33 per share, with no cost reported for the option itself.
All 750,000 derivative securities are shown as beneficially owned directly after the grant. The option vests over four years: 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the option is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026. These options give him the right to buy those shares at an exercise price of $2.33 per share. The grant was reported as a direct beneficial ownership position, with 750,000 derivative securities held after the transaction.
According to the vesting terms, 25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years. This structure means the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date, aligning the officer’s potential equity ownership with longer-term service to the company.
Neumora Therapeutics, Inc. reported a new equity award for President Joshua PintoJanuary 8, 2026, he was granted an option to purchase 1,200,000 shares of common stock at an exercise price of $2.33 per share. According to the vesting terms, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
Neumora Therapeutics, Inc. reported that Chief Executive Officer and Chairman of the Board Paul L. Berns received a grant of stock options on January 8, 2026. The Form 4 shows an award of 1,650,000 stock options, each with an exercise price of $2.33 per share, giving him the right to buy common stock at that price. The options were acquired as a derivative security and are held directly, with 1,650,000 derivative securities beneficially owned following the transaction.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the entire grant is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics (NMRA) officer Daljit Singh Aurora reported an open-market sale of 114,703 shares of common stock on 11/11/2025 at a weighted average price of $2.6767. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024, and the sold shares were held by the Aurora Family Trust. Following the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.
Neumora Therapeutics (NMRA) insider filing: Director and 10% owner Kristina Burow reported a purchase of 1,915,700 shares of common stock at $2.61 on 10/27/2025, recorded as an indirect transaction by ARCH Venture Fund XII, L.P.
Following the transaction, reported beneficial holdings include: 6,046,907 shares indirectly via ARCH Venture Fund XII, L.P.; 1,387,228 via ARCH Venture Fund VII, L.P.; 2,321,566 via ARCH Venture Fund VIII Overage, L.P.; 12,205,379 via ARCH Venture Fund X, L.P.; 11,886,758 via ARCH Venture Fund X Overage, L.P.; and 47,717 shares held directly.
Neumora Therapeutics (NMRA) insider filing reports an open-market purchase by affiliated ARCH Venture funds. On 10/27/2025, the reporting persons acquired 1,915,700 shares of common stock at $2.61 per share, reported as indirectly owned.
Following the transaction, indirect beneficial holdings were listed as: 6,046,907 shares by ARCH Venture Fund XII, L.P.; 1,387,228 by ARCH Venture Fund VII, L.P.; 2,321,566 by ARCH Venture Fund VIII Overage, L.P.; 12,205,379 by ARCH Venture Fund X, L.P.; and 11,886,758 by ARCH Venture Fund X Overage, L.P. The filing is a joint submission, and a director relationship is indicated.
Neumora Therapeutics (NMRA): ARCH-affiliated reporting persons disclosed an insider purchase. On 10/27/2025, ARCH Venture Fund XII, L.P. bought 1,915,700 shares of common stock at $2.61 per share (Transaction Code P), reported as indirect ownership.
After the transaction, beneficial holdings reported include: 6,046,907 (ARCH XII); 12,205,379 (ARCH Venture Fund X, L.P.); 11,886,758 (ARCH Venture Fund X Overage, L.P.); 2,321,566 (ARCH Venture Fund VIII Overage, L.P.); and 1,387,228 (ARCH Venture Fund VII, L.P.). The filing was made jointly by multiple ARCH entities and certain individuals, with the relationship indicated as Director.